I. Introduction to Fungal Pathogenesis and Antifungal Targets

Fungi are eukaryotic organisms, which presents a challenge for drug development: selective toxicity. Antifungal agents primarily target structures or processes unique to fungal cells, minimizing harm to host cells.

Key Fungal Cell Targets

II. Polyenes: Ergosterol Binders

Mechanism of Action

Polyenes exert their effect by directly binding to ergosterol, a crucial component of the fungal cell membrane. This binding creates pores or channels in the membrane, leading to increased permeability, leakage of intracellular ions (e.g., K⁺), and ultimately cell death. They are generally fungicidal.

Key Drugs and Clinical Considerations

III. Azoles: Ergosterol Synthesis Inhibitors

Mechanism of Action

Azoles inhibit 14-alpha-demethylase (a cytochrome P450 enzyme, CYP51) responsible for converting lanosterol to ergosterol. This inhibition leads to accumulation of toxic methylated sterols and depletion of ergosterol, impairing fungal cell membrane integrity and function. They are generally fungistatic.

Sub-classes and Key Drugs

Azoles are divided into Imidazoles and Triazoles, with triazoles generally having better systemic absorption, longer half-lives, and fewer drug interactions (though still significant).

IV. Echinocandins: Cell Wall Inhibitors

Mechanism of Action

Echinocandins are a relatively new class of antifungals that target the fungal cell wall, a structure absent in human cells. They inhibit beta-(1,3)-D-glucan synthase, an enzyme essential for the synthesis of beta-(1,3)-D-glucan, a major component of the fungal cell wall. This leads to osmotic instability and cell lysis. They are generally fungicidal against Candida and fungistatic against Aspergillus.

Key Drugs and Clinical Uses

V. Other Antifungal Agents

A. Flucytosine (5-FC): Nucleic Acid Synthesis Inhibitor

Flucytosine is a synthetic pyrimidine antimetabolite. It is converted to 5-fluorouracil (5-FU) by fungal cytosine deaminase (an enzyme absent in human cells). 5-FU is then converted to 5-fluorodeoxyuridine monophosphate, which inhibits DNA synthesis, and 5-fluorouridine triphosphate, which is incorporated into RNA, inhibiting protein synthesis. It is typically fungistatic and used in combination with Amphotericin B for synergistic effect and to prevent resistance.

B. Allylamines and Benzylamines: Squalene Epoxidase Inhibitors

This class inhibits squalene epoxidase, an enzyme early in the ergosterol biosynthesis pathway. This leads to the accumulation of toxic squalene and a deficiency of ergosterol, disrupting cell membrane function. They are primarily used for dermatophyte infections.

C. Griseofulvin: Microtubule Inhibitor

Griseofulvin interferes with fungal cell mitosis by disrupting the mitotic spindle and inhibiting microtubule function. It also binds to keratin in newly forming skin, hair, and nails, protecting them from infection. It is fungistatic.

D. Other Topical Antifungals

VI. Key Considerations in Antifungal Therapy

A. Fungal Resistance Mechanisms

• Target modification: Mutations in enzymes like 14-alpha-demethylase (for azoles) or beta-(1,3)-D-glucan synthase (for echinocandins).
• Efflux pumps: Overexpression of transporter proteins that pump drugs out of the fungal cell.
• Reduced drug uptake: Alterations in cell membrane or wall reducing drug penetration.
• Bypass mechanisms: Fungi developing alternative metabolic pathways.

B. Drug Interactions

As highlighted with azoles, cytochrome P450 inhibition is a major concern, particularly with CYP3A4, leading to elevated levels of co-administered drugs. Clinicians must always review patient medication lists for potential interactions.

C. Toxicity Profiles

Each class has unique toxicity concerns (e.g., nephrotoxicity with Amphotericin B, hepatotoxicity with azoles and terbinafine, bone marrow suppression with flucytosine). Patient monitoring and appropriate dose adjustments are essential.

D. Duration of Therapy

Antifungal treatments often require prolonged courses, especially for systemic or invasive infections (weeks to months), due to the slow growth of fungi and the nature of these infections.